Patient experience in a randomized trial of a weekly progesterone vaginal ring versus a daily progesterone gel for luteal support after in vitro fertilization Elizabeth S. Ginsburg, M.D., Teru Jellerette-Nolan, Ph.D., Gaurang Daftary, M.D., M.B.A., Yunling Du, Ph.D., Kaylen M. Silverberg, M.D. Fertility and Sterility Volume 110, Issue 6, Pages 1101-1108.e3 (November 2018) DOI: 10.1016/j.fertnstert.2018.07.014 Copyright © 2018 The Authors Terms and Conditions
Figure 1 Percentage of women who responded that various aspects of using their assigned progesterone (PGN) medication were (A) “easy or somewhat easy,” (B) “not at all a problem,” (C) “not stressful,” or (D) “caused no interference.” aP<.001 versus gel; bP<.01 versus gel; cP<.05 versus gel. Fertility and Sterility 2018 110, 1101-1108.e3DOI: (10.1016/j.fertnstert.2018.07.014) Copyright © 2018 The Authors Terms and Conditions
Figure 2 Percentage of women who had intercourse during treatment and reported that they or their partner were not at all bothered by progesterone (PGN) medication during intercourse. aP<.001 versus gel. Fertility and Sterility 2018 110, 1101-1108.e3DOI: (10.1016/j.fertnstert.2018.07.014) Copyright © 2018 The Authors Terms and Conditions
Figure 3 Responses from the subset of women who had previously used a different progesterone (PGN) medication indicating how their current method compared with their previous method. aP<.001 versus gel. Fertility and Sterility 2018 110, 1101-1108.e3DOI: (10.1016/j.fertnstert.2018.07.014) Copyright © 2018 The Authors Terms and Conditions